Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Agilent Technologies (A) will participate in a fireside chat at the J.P. Morgan U.S. All Stars Conference at 10 a.m. BST on Sept. 23, 2026, in London.
CEO Padraig McDonnell and CFO Adam Elinoff are scheduled to speak. A live audio webcast and replay of the presentation will be available via Agilent’s Investor Relations website. The company reports revenue of $6.95 billion for fiscal year 2025 and has approximately 18,000 employees worldwide.
Agilent Technologies (A) announced the retirement of independent board chair Koh Boon Hwee, effective Sept. 4, 2026, after more than 20 years as a director.
He joined the board in 2003, became independent chair in 2017, and led the Executive Committee and the Nominating and Corporate Governance Committee. Following his retirement, the board elected Dow R. Wilson as chair, also effective Sept. 4, 2026; Wilson has served as a director since 2018 and chairs the Audit and Finance Committee. Agilent also appointed Glenn Boehnlein, former Stryker Corporation CFO, to its board on the same date. The company reports fiscal 2025 revenue of $6.95 billion and a workforce of about 18,000 employees worldwide.
Agilent Technologies (A) has launched the Agilent S540MD Slide Scanner System in the United States, a whole slide imaging digital scanner cleared by the FDA for use in digital pathology workflows.
The S540MD supports up to 540 slides, offers continuous loading and standard rack compatibility, and includes automated scanning modes with advanced tissue detection to help high-volume pathology laboratories digitize glass slides efficiently. The scanner is an Agilent-branded version of the Hamamatsu NanoZoomer S540MD system. Agilent states that this launch strengthens its digital pathology portfolio and supports laboratories facing rising sample volumes and the shift toward digital and AI-enabled workflows. The system is now available across the U.S. and in multiple European markets following an earlier launch in select European countries in January 2026.
Agilent Technologies (NYSE: A) has launched the Cary 635 FTIR spectrometer, a compact, high-performance Fourier transform infrared system designed to meet modern laboratory demands for efficiency, reliability, and space savings. The instrument features solid ZnSe optics for moisture resistance, improved sensitivity for lower-concentration samples, and a highly modular architecture that supports solids, liquids, powders, and gases.
The Cary 635 FTIR incorporates a nondynamic interferometer, permanently aligned optics for rapid module changes, and compatibility with the Agilent DialPath module to simplify liquid measurements while reducing consumables and sample volume. Method-driven MicroLab software offers guided workflows and color-coded results, enabling rapid training of users and supporting both routine and complex applications. Agilent reports fiscal 2025 revenue of $6.95 billion and a workforce of about 18,000 employees worldwide.
Agilent (NYSE: A) reported third-quarter fiscal 2026 revenue of $1.88 billion, up 8.1% reported and 7.3% core versus Q3 2025. GAAP operating margin reached 23.6%, while non-GAAP operating margin was 28.3%, including an approximately 110 bps net benefit from tariff refunds. GAAP net income was $362 million (EPS $1.28), and non-GAAP net income was $459 million with EPS of $1.62, up 18% year-over-year.
By segment, Life Sciences and Diagnostics revenue was $746 million (+11% reported), Agilent CrossLab $786 million (+6%), and Applied Markets $346 million (+7%). Agilent raised its fiscal 2026 outlook, guiding revenue to $7.49–$7.51 billion (7.8%–8.1% reported growth) and non-GAAP EPS to $6.18–$6.21. Fourth-quarter 2026 revenue is expected at $1.98–$2.0 billion with non-GAAP EPS of $1.71–$1.74, excluding any future tariff refund benefits.
TORM plc (Nasdaq: TRMD, TRMD A) has appointed Jann Brown to its Board of Directors, effective 1 October 2026, following a planned succession process. The company states that the move supports its focus on governance, continuity, and long-term value creation for shareholders.
The Board has also promoted Annette Malm Justad to Senior Independent Director to further enhance governance and shareholder engagement. Brown brings extensive international finance, risk management, strategy, and corporate governance experience from executive and non-executive roles in several sectors.
Agilent Technologies (NYSE: A) has presented an Agilent Research Catalyst (ARC) Award to the Eastern Institute of Technology, Ningbo, recognizing Professor Zongwei Cai’s work on advanced analytical methods for detecting PFAS and other emerging contaminants. The award provides research funding and Agilent instrumentation to support mass spectrometry-based detection, innovative sample preparation, and organoid-based toxicology platforms, aiming to better link contaminant measurement with biological impact and improve environmental monitoring and risk assessment.
Agilent Technologies (NYSE: A) plans to release its third-quarter fiscal year 2026 financial results after the U.S. stock market closes on Wednesday, Aug. 26, 2026. The company will host a listen-only conference call to discuss the results at 1:30 p.m. PDT the same day, accessible via the Events section of Agilent’s Investor Relations website. A recording of the call will be available online for 90 days.
Agilent describes itself as a global leader in analytical and clinical laboratory technologies, offering instruments, software, services, and expertise. According to the company, it generated $6.95 billion in revenue in fiscal year 2025 and employs about 18,000 people worldwide.
Agilent (NYSE: A) received European Union certification for its PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to help identify patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA (pembrolizumab).
According to Agilent, this is the eighth CE-marked companion diagnostic indication for PD-L1 IHC 22C3 pharmDx in the EU. The assay supported patient selection in the KEYNOTE-B96/ENGOT-ov65 trial in the platinum-resistant setting and is already indicated in the EU for several other tumor types, including NSCLC, esophageal, cervical, HNSCC, TNBC, gastric/GEJ adenocarcinoma, and urothelial carcinoma.
Agilent Technologies (NYSE: A) received U.S. FDA approval for its PD‑L1 IHC 28‑8 pharmDx assay as a companion diagnostic in esophageal squamous cell carcinoma (ESCC), gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma. The test identifies patients whose tumors express PD‑L1 (Combined Positive Score [CPS] ≥ 1) and who may be eligible for treatment with Bristol Myers Squibb’s OPDIVO (nivolumab) or OPDIVO QVANTIG (nivolumab and hyaluronidase‑nvhy).
According to Agilent, PD‑L1 IHC 28‑8 pharmDx (Code SK005) is FDA‑approved for exclusive use on the Agilent Autostainer Link 48 platform and was developed in partnership with Bristol Myers Squibb within the OPDIVO clinical program. The company notes that CheckMate‑648 and CheckMate‑649 studies showed improved overall and progression‑free survival with OPDIVO‑based regimens in these tumors, underscoring the role of accurate PD‑L1 testing. Agilent positions this approval as reinforcing its leadership in immunohistochemistry‑based diagnostics and drug‑diagnostic co‑development, supporting precision oncology in cancers that together account for over 1.4 million new cases and more than 1.1 million deaths globally each year.